Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 661 publications

Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.

Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.

Journal: JAMA network open
Published: October 02, 2025

Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors.

Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors.

Journal: Biochemical pharmacology
Published: July 14, 2025

LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes.

LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes.

Journal: JCO precision oncology
Published: July 09, 2025

Effectiveness and Safety of PARP Inhibitors in Ovarian Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses.

Effectiveness and Safety of PARP Inhibitors in Ovarian Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses.

Journal: Critical reviews in oncology/hematology
Published: July 04, 2025

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging.

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging.

Journal: EJNMMI radiopharmacy and chemistry
Published: July 03, 2025

Rucaparib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome.

Rucaparib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome.

Journal: Cureus
Published: June 17, 2025

The emerging role of PARP inhibitors in prostate cancer: A narrative review.

The emerging role of PARP inhibitors in prostate cancer: A narrative review.

Journal: Cancer treatment reviews
Published: June 16, 2025

Rucaparib induces mitochondrial fragmentation and apoptosis in prostate cancer cells by targeting Drp1.

Rucaparib induces mitochondrial fragmentation and apoptosis in prostate cancer cells by targeting Drp1.

Journal: Investigational new drugs
Published: June 10, 2025

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.

Journal: Journal for immunotherapy of cancer
Published: May 28, 2025

Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 19, 2025

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.

Journal: Gynecologic oncology
Published: May 12, 2025

Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy.

Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy.

Journal: Pathology, research and practice
Published: May 05, 2025
Showing 1-12 of 661

Last Updated: 10/31/2025